Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
quarterly or semiannual financial statement / - Above-average growth in results by 21.1% to EUR 7 million according to DVFA - Revenue rises in 1st half year of 2006/2007 to EUR 107.8 million - Further revenue and re

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 08.02.2007 Berlin, 8th February 2007. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) has been able to further enhance its revenues in the first half-year period of the 2006/2007 financial year by EUR 4.5 million to EUR 107.8 million (previous year: EUR 103.3 million). The result according to DVFA/SG (IFRS) was increased by EUR 1.2 million from EUR 5.8 million to the current level of EUR 7.0 million. The result therefore increased disproportionately high compared to the growth in revenues by 21.1%. The result per share according to DVFA reached EUR 0.63 following EUR 0.58 in the same period for the previous year. The profit enhancement is still a result of the core segment of care, even though the negative profit contribution in the rehabilitation segment has been significantly reduced. In the period of reporting, the care segment achieved an increase in revenues of EUR 2.9 million to a total of EUR 81.8 million compared to EUR 78.9 million in the previous year. In the result according to DVFA/SG (IFRS), the care segment achieved a result of EUR 7.6 million (previous year: EUR 7.0 million) and a current capacity utilisation of 92.6% (previous year: 91.9%). Continued improvement is becoming evident in the rehabilitation segment. It was possible to improve both revenue as well as profit compared to the previous year. In the first six months of the 2006/2007 financial year, the revenue could be enhanced by EUR 1.7 million to EUR 26.1 million compared to the previous year. It was possible to reduce the loss contributions for this segment. With EUR -0.6 million (previous year: EUR -1.2 million) the burden on the overall result which was contributed by the result according to DVFA/SG (IFRS) was lower by EUR 0.6 million. This in particular should also be viewed as a success since the rehabilitation segment in the first quarter was burdened by the after-effects of the physicians’ strike. This also explains the capacity reversal, which in the remaining clinics fell from 77.2% to 76.3% when comparing the two six-month periods. In the period of reporting, Marseille-Kliniken AG was able to expand the number of beds to a total of 8,612 beds (+444 beds), of which more than 83% are in the care segment. For the remainder of the 2006/2007 financial year, the company is planning to further accelerate its revenue and profit growth. The positive occupancy development which has already occurred in the care segment will have an even greater effect in the 3rd and 4th quarters. The growth strategy will be implemented systematically, and contracts have been drawn up to ensure a further 1,000 beds for this, which will be brought into use successively. The detailed shareholders’ letter for the first half year of 2006/2007 is now available on the Internet at End of the ad-hoc release end of announcement euro adhoc 08.02.2007 07:05:23 -------------------------------------------------------------------------------- ots Originaltext: Marseille-Kliniken AG Im Internet recherchierbar: Further inquiry note: Branche: Pharmaceuticals ISIN: DE0007783003 WKN: 778300 Index: CDAX, Classic All Share, Prime All Share Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard Börse Berlin-Bremen / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Hamburger Wertpapierbörse / official dealing

Das könnte Sie auch interessieren: